Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | CD4 | P01730 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387319 | 0.90 | ALDH1A1 (0.47) | LMNASMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL4393905 | 0.89 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL4393170 | 0.89 | PKM (0.49) | LMNASMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL4381221 | 0.87 | LMNA (0.43) | LMNASMN1; SMN2ALDH1A1MAPTTSHR | |
| SCHEMBL4381771 | 0.87 | LMNA (0.50) | LMNASMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL4376971 | 0.87 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL4385187 | 0.86 | IKBKB (0.42) | LMNASMN1; SMN2TSHRMAPK1L3MBTL1 | |
| SCHEMBL4376950 | 0.85 | LMNA (0.42) | LMNASMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL4393979 | 0.85 | IKBKB (0.41) | LMNASMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL4395422 | 0.85 | SMN1; SMN2 (0.39) | LMNASMN1; SMN2ALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | LMNA 3822/4885SMN1; SMN2 664/4885ALDH1A1 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.